Aquaporumab, a competitive inhibitor of AQP4, is under investigation.13 These innovative treatments have no proven efficacy for treatment of neuropsychiatric lupus, which underscores the importance of correctly diagnosing the etiology of LETM in every patient, particularly in SLE patients. The gene discussed is AQP4; the disease is systemic lupus erythematosus.